Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152

@article{Ganneru2020EvaluationOS,
  title={Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152},
  author={Brunda Ganneru and Harsh Jogdand and Vijaya Kumar Dharam and Narasimha Reddy Molugu and Sai D. Prasad and Srinivas Vellimudu and Krishna M Ella and Rajaram Ravikrishnan and Amit Awasthi and Jomy Jose and P. Jayaprakash Rao and Deepak Kumar and Raches Ella and Priya Abraham and Pragya D. Yadav and Gajanan N. Sapkal and Anita M Shete and Gururaj Rao Desphande and Sreelekshmy Mohandas and Atanu Basu and Nivedita Gupta and Krishna Mohan Vadrevu},
  journal={bioRxiv},
  year={2020}
}
We report the development and evaluation of safety and immunogenicity of a whole virion inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or a novel TLR7/8 agonist adsorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established vero cell platform to produce large-scale GMP grade highly purified inactivated antigen, BBV152. Product development and manufacturing were carried out in a BSL-3 facility. Immunogenicity was determined at two… Expand
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
TLDR
Interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152, 3{ micro} and 6{micro} with Algel-IMDG suggest that the safety profile of this vaccine is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates. Expand
Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt
TLDR
It is concluded that the vaccine described here has safety and desirable properties, and the data support further development and plans for clinical trials, and immunogenicity of the developed vaccine indicated the high antigen-binding and neutralizing antibody titers, regardless of the dose concentration. Expand
Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
TLDR
The considerable immunological aspects, potential antigen targets, appropriate adjuvants as well as key points in the various stages of COVID-19 vaccine development are introduced and the principal features of the preclinical and clinical studies of pioneering COVID -19 vaccine candidates were pointed out. Expand
Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration
TLDR
It is stressed that thermostabilizing technologies are available to enable cold chain-free vaccine storage and distribution, as well as potential needle-free vaccination. Expand
SARS-CoV-2: Targeted managements and vaccine development
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in diverse outcomes. The symptoms appear to be more severe in males older than 65 and people with underlyingExpand

References

SHOWING 1-10 OF 44 REFERENCES
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
TLDR
Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. Expand
Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
TLDR
A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year that corroborate with excellent seroprotection after the first dose of an earlier J ENVAC study and report appreciable interchangeability between both vaccines. Expand
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
TLDR
The experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging SARS-CoV-2 are discussed. Expand
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans. Expand
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
TLDR
Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS. Expand
Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine
TLDR
It is found that TLR stimulation reduced the high level of eosinophilic infiltration that occurred in the lungs of mice immunized with UV-inactivated SARS-CoV, suggesting that vaccine-induced eos inophil immunopathology in the Lungs upon SARS -CoV infection could be avoided by the TLR agonist adjuvants. Expand
Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine.
TLDR
It can be concluded that Indirab is as safe and immunogenic as Verorab when administered by both intramuscular and intradermal routes. Expand
A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains.
TLDR
JENVAC elicits long-lasting, broadly protective immunity and neutralized JEV genotypes I, II, III, and IV equally well, and immunogenicity criteria were higher than that for SA-14- 14-2 at 12, 18, and 24 months each. Expand
Two Doses of Parenterally Administered Split Influenza Virus Vaccine Elicited High Serum IgG Concentrations which Effectively Limited Viral Shedding upon Challenge in Mice
TLDR
The concentration of postvaccination serum IgG showed an inverse relationship with the level of viral shedding after viral challenge, and is an important factor in limiting viral replication in the upper respiratory tract upon challenge of an antigenically similar virus. Expand
Inactivated Viral Vaccines
TLDR
The principles of viral inactivation and the application of these principles to vaccine development are described and the manufacturing procedure and the accompanying assays, of which assays used for monitoring the inactivation process and preservation of neutralizing epitopes, are pivotal. Expand
...
1
2
3
4
5
...